Cargando…

Toxicity of Checkpoint Inhibition in Advanced RCC: A Systematic Review

BACKGROUND: Checkpoint inhibitors (CPI) have now been established as standard agents in the management of patients with metastatic renal cell carcinoma (mRCC). Given the unique toxicity profiles of CPIs, a detailed understanding of their incidence rate and characteristics is critical. OBJECTIVE: To...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ornstein, Moshe C., Garcia, Jorge A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2017
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6179114/ https://www.ncbi.nlm.nih.gov/pubmed/30334015 http://dx.doi.org/10.3233/KCA-170017

Ejemplares similares

Tailoring Immunotherapy Treatment of Synchronous Renal Cell Carcinoma (RCC) and Triple-Negative Breast Cancer (TNBC)
por: Sheng, Iris Y., et al.
Publicado: (2019)

A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy
por: Ornstein, Moshe C., et al.
Publicado: (2019)

The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF Inhibition
por: Barata, Pedro C., et al.
Publicado: (2017)

Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis
por: Tzeng, Alice, et al.
Publicado: (2021)

OPtimal Treatment by Invoking biologic clusters in renal cell carcinoma (OPTIC RCC)
por: Beckermann, Kathryn, et al.
Publicado: (2023)

Screening for functional kinases in metastatic prostate cancer: a glimmer of hope for kinase inhibition
por: Ornstein, Moshe C., et al.
Publicado: (2016)

Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor
por: Ornstein, Moshe C., et al.
Publicado: (2023)

Correction to: Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor
por: Ornstein, Moshe C., et al.
Publicado: (2023)

Impact of age on the toxicity of immune checkpoint inhibition
por: Samani, Amit, et al.
Publicado: (2020)

Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model
por: Yuen, J S P, et al.
Publicado: (2011)

Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook
por: Gopalakrishnan, Dharmesh, et al.
Publicado: (2018)

A Systematic Review of the Efficacy and Safety Experience Reported for Sorafenib in Advanced Renal Cell Carcinoma (RCC) in the Post-Approval Setting
por: Fishman, Mayer N., et al.
Publicado: (2015)

Systematic Review: ClearCode 34 – A Validated Prognostic Signature in Clear Cell Renal Cell Carcinoma (ccRCC)
por: Ghatalia, Pooja, et al.
Publicado: (2018)

Pivotal biomarker expression and drug screening in advanced ccRCC
por: Xiao, Wen, et al.
Publicado: (2020)

Cytoreductive Nephrectomy Following Immunotherapy-Base Treatment in Metastatic Renal Cell Carcinoma: A Case Series and Review of Current Literature
por: Dawsey, Scott J., et al.
Publicado: (2021)

RCC prolapse causing Aortic regurgitation in a restrictive VSD
por: Abqari, S, et al.
Publicado: (2015)

A New Treatment Landscape for RCC: Association of the Human Microbiome with Improved Outcomes in RCC
por: Piao, Xuan-Mei, et al.
Publicado: (2023)

SDHB Suppresses the Tumorigenesis and Development of ccRCC by Inhibiting Glycolysis
por: Fang, Zhiyu, et al.
Publicado: (2021)

The negative effect of antibiotics on RCC patients with immunotherapy: A systematic review and meta-analysis
por: Luo, Zhiqiang, et al.
Publicado: (2022)

Addition of Salvage Immunotherapy to Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma
por: Dawsey, Scott J., et al.
Publicado: (2021)

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review
por: Shalata, Walid, et al.
Publicado: (2021)

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review
por: Cozma, Angela, et al.
Publicado: (2022)

Molecular subtypes and prognosis in RCC
por: Beuselinck, Benoit, et al.
Publicado: (2015)

Open Surgery for Localized RCC
por: Vander Eeckt, Kathy, et al.
Publicado: (2007)

Urine Metabolomics for Renal Cell Carcinoma (RCC) Prediction: Tryptophan Metabolism as an Important Pathway in RCC
por: Liu, Xiaoyan, et al.
Publicado: (2019)

Lower risk of severe checkpoint inhibitor toxicity in more advanced disease
por: Verheijden, Rik J, et al.
Publicado: (2020)

Radiation and Checkpoint Inhibitor Immunotherapy Lead to Long Term Disease Control in a Metastatic RCC patient With Brain Metastases
por: Levitin, Maria, et al.
Publicado: (2020)

Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors
por: Kaymakcalan, M D, et al.
Publicado: (2013)

Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy
por: Jeyakumar, Ghayathri, et al.
Publicado: (2017)

Safety and clinical efficacy of everolimus in the treatment of advanced renal cell carcinoma (RCC)
por: Shahani, Rohan, et al.
Publicado: (2010)

A mechanism of coupling RCC1 mobility to RanGTP production on the chromatin in vivo
por: Li, Hoi Yeung, et al.
Publicado: (2003)

Immune-Checkpoint Induced Skin Toxicity Masked as Squamous Cell Carcinoma: Case Report on Mimickers of Dermatological Toxicity with PD-1 Inhibition
por: Chan, Sze Wah Samuel, et al.
Publicado: (2023)

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature
por: Agrawal, Nikhil, et al.
Publicado: (2019)

Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Cancer (RCC)
por: Bregni, Marco, et al.
Publicado: (2011)

Laparoscopic cytoreductive nephrectomy and adrenalectomy for metachronous RCC metastases—Case report
por: Petrut, Bogdan, et al.
Publicado: (2020)

Checkpoint Inhibition in the Treatment of Unresectable, Advanced Lymphoepithelioma-like Hepatocellular Carcinoma
por: Hermel, David J., et al.
Publicado: (2021)

Untangling ccRCC prognosis with SLINKY
por: Reinfeld, Bradley I., et al.
Publicado: (2017)

The Multifaceted Roles of RCC1 in Tumorigenesis
por: Ren, Xuanqi, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management
por: Seethapathy, Harish, et al.
Publicado: (2021)

The Impact Of Succinate Dehydrogenase Gene (SDH) Mutations In Renal Cell Carcinoma (RCC): A Systematic Review
por: Aghamir, Seyed Mohammad Kazem, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pip5ev1fc740fnr1a6q4rptqps